Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.
Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Type:
Grant
Filed:
September 15, 2015
Date of Patent:
December 12, 2017
Assignee:
Expression Pathology, Inc.
Inventors:
David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
Abstract: The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
Type:
Grant
Filed:
October 31, 2013
Date of Patent:
December 5, 2017
Assignees:
Takeda GmbH, Amgen Research (Munich) GmbH
Inventors:
Markus Rast, Wolfram Steinhilber, Christian de Muynck, Gerhard Becker, Pernille Dybendal Pedersen, Thomas Urbig, Thomas Boehm
Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
Type:
Grant
Filed:
July 25, 2013
Date of Patent:
October 31, 2017
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
Abstract: Methods for increasing immunoglobulin A (IgA) levels in a subject having a deficiency thereof are provided herein by administering to the subject an agent that inhibits CXCL13 activity, such as an anti-CXCL13 or an anti-CXCR5 antibody. Further provided are methods for treating an inflammatory disorder in a subject deficient for IgA by administering to the subject an agent that inhibits CXCL13 activity.
Type:
Grant
Filed:
January 31, 2014
Date of Patent:
October 17, 2017
Assignee:
Vaccinex, Inc.
Inventors:
Maurice Zauderer, Masaru Yoshida, Koji Yamamoto, Ernest S. Smith
Abstract: Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.
Type:
Grant
Filed:
December 14, 2009
Date of Patent:
October 17, 2017
Assignee:
UNIVERSITY OF BRITISH COLUMBIA
Inventors:
Aziz Ghahary, Wolodymyr Walter Peter Maksymowych, Ruhangiz Taghi Kilani
Abstract: Provided herein are methods of increasing lipoprotein lipase (LPL) activity, by inhibiting apolipoprotein C3 (ApoCIII), which removes the ApoCIII inhibition of LPL, and permits VLDL to be converted to LDL. Also provided are methods for treating or preventing a lipid metabolism disorder, such as type 2 diabetes by use of an ApoCIII antagonist. Also provided are screening methods to identify ApoCIII antagonists.
Type:
Grant
Filed:
February 25, 2014
Date of Patent:
October 10, 2017
Assignee:
iMBP Holding, LLC
Inventors:
Urban A. Kiernan, David A. Phillips, Eric E. Niederkofler
Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
Abstract: This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
Type:
Grant
Filed:
November 9, 2015
Date of Patent:
September 19, 2017
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Disclosed herein is the use of an active agent comprising a peptide derived from atrial natriuretic peptide (ANP) prohormone or a mimetic thereof in the manufacture of a medicament for treating a disease in a subject. The medicament is administered subcutaneously in a multimodal dosage regime comprising at least an initial dosage stage and at least one maintenance dosage stage. The initial dosage stage comprises infusing the active agent at an initial dosage rate for an initial period to achieve a target steady state blood plasma concentration of the active agent or metabolite thereof. The maintenance dosage stage(s) comprise(s) adjusting the dosage rate to a maintenance dosage rate for a maintenance period to substantially maintain said target steady state blood plasma concentration of the active agent or metabolite thereof.
Type:
Grant
Filed:
September 14, 2015
Date of Patent:
September 19, 2017
Assignee:
MADELEINE PHARMACEUTICALS PTY LTD
Inventors:
Thomas Robert Geimer, Richard Neil Upton
Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.
Type:
Grant
Filed:
September 21, 2015
Date of Patent:
September 12, 2017
Assignee:
ProThera Biologics, Inc.
Inventors:
Yow-Pin Lim, Edward S. Sirya, Peter Brne
Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
August 29, 2017
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
Abstract: A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease. Similar methods for diagnosing irritable bowel syndrome are also described. Various companion therapeutic methods and useful binding reagents are also described.
Abstract: The present invention provides antibodies which bind to the Delta/Serrate/LAG-2 consensus sequence (DSL) domain of human Jagged 1 via novel epitopes comprising the residue E228, and inhibit the interaction between human Jagged 1 and its associated receptors. Said antibodies may be administered therapeutically in the treatment of tumors/cancer, preferably those associated with tumoral Jagged 1-mediated signalling and tumor microenvironmental processes in which Jagged 1 and/or Notch-mediated signalling has been implicated, including those comprising Jagged 1-mediated cross talk between the tumor and the tumor microenvironment. The present invention also provides pharmaceutical compositions comprising said antibodies, uses of said antibodies in therapy, hybridomas comprising and/or secreting said antibodies and cells or cell lines expressing said antibodies and humanized/deimmunized variants in recombinant form.
Type:
Grant
Filed:
January 15, 2014
Date of Patent:
August 8, 2017
Assignee:
Cancer Research Technology Limited
Inventors:
Alison Hilary Banham, Adrian Llewellyn Harris, Penelope Ann Handford, Susan Mary Lea
Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.
Type:
Grant
Filed:
September 6, 2013
Date of Patent:
August 1, 2017
Assignees:
Adelaide Research & Innovation PTY LTD, Peter Maccallum Cancer Institute
Inventors:
Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
Abstract: The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.
Type:
Grant
Filed:
May 27, 2015
Date of Patent:
August 1, 2017
Assignee:
MedImmune, LLC
Inventors:
Melissa Damschroder, Michael Oberst, Scott Hammond, Hui Feng